-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ensifentrine in Allergic Asthma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ensifentrine in Allergic Asthma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ensifentrine in Allergic Asthma Drug Details: Ensifentrine (RPL-554) is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – (Avibactam + Aztreonam) in Hospital Acquired Pneumonia (HAP)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - (Avibactam + Aztreonam) in Hospital Acquired Pneumonia (HAP) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. (Avibactam + Aztreonam) in Hospital Acquired Pneumonia (HAP)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Rogaratinib in Metastatic Transitional (Urothelial) Tract Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Rogaratinib in Metastatic Transitional (Urothelial) Tract Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Rogaratinib in Metastatic Transitional (Urothelial) Tract Cancer Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ricolinostat in Chronic Lymphocytic Leukemia (CLL)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ricolinostat in Chronic Lymphocytic Leukemia (CLL) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ricolinostat in Chronic Lymphocytic Leukemia (CLL) Drug Details: Ricolinostat (ACY-1215)...
-
Company Insights
Innovation and Patenting activity of My EG Services Bhd Q1 2024
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of My EG Services Bhd Q1 2024". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Itacitinib Adipate in Non-Hodgkin Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Itacitinib Adipate in Non-Hodgkin Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Itacitinib Adipate in Non-Hodgkin Lymphoma Drug Details: Itacitinib adipate (INCB-39110)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – EG-501 in Cognitive Impairment
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - EG-501 in Cognitive Impairment report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.EG-501 in Cognitive ImpairmentDrug Details:EG-501 is under development for the treatment of cognitive...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – EG-017 in Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - EG-017 in Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. EG-017 in...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – EG-501 in Systemic Lupus Erythematosus
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - EG-501 in Systemic Lupus Erythematosus report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.EG-501 in Systemic Lupus Erythematosus Drug Details:EG-501 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – EG-001 in Idiopathic Interstitial Pneumonia (IIP)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - EG-001 in Idiopathic Interstitial Pneumonia (IIP) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.EG-001 in Idiopathic Interstitial Pneumonia (IIP)Drug Details:EG-001 is under development for...